LFG
VKTX icon

Larson Financial Group’s Viking Therapeutics VKTX Stock Holding History

Larson Financial Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.61K Sell
195
-708
-78% -$22.9K ﹤0.01% 2559
2026
Q1 		$29.4K Buy
903
+714
+378% +$22.9K ﹤0.01% 1641
2025
Q4 		$6.65K Buy
189
+16
+9% +$567 ﹤0.01% 2338
2025
Q3 		$4.55K Buy
173
+157
+981% +$4.68K ﹤0.01% 2389
2025
Q2 		$424 Sell
16
-3
-16% -$79 ﹤0.01% 2905
2025
Q1 		$459 Sell
19
-19
-50% -$601 ﹤0.01% 2601
2024
Q4 		$1.53K Sell
38
-81
-68% -$4.62K ﹤0.01% 1938
2024
Q3 		$7.53K Buy
119
+103
+644% +$6.04K ﹤0.01% 1583
2024
Q2 		$848 Buy
+16
New +$1.05K ﹤0.01% 1740

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Larson Financial Group's VKTX Position: Q2 2026 in Review

Larson Financial Group reduced its Viking Therapeutics (VKTX) stake by 78% in Q2 2026, selling an estimated $22.9K and leaving 195 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

Larson Financial Group first reported a position in VKTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $29.4K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Larson Financial Group held 195 shares of Viking Therapeutics worth $7.61K as of Q2 2026.
  • Larson Financial Group sold 708 Viking Therapeutics shares in Q2 2026, an estimated $22.9K.
  • Viking Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2559 holding.
  • Larson Financial Group first reported a position in Viking Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Larson Financial Group's Viking Therapeutics position peaked at $29.4K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.